Sparsentan Versus Irbesartan in Pediatric Patients With FSGS
Kidney International Reports – 2026
Search Results
Filter by:
Information type
Information type
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Study type
Study type
×Resource type
Resource type
×Filter by:
Information type
Information type
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Study type
Study type
×Sort by
Publications
Results57
Review of the Clinical, Humanistic, and Economic Burden of Focal Segmental Glomerulosclerosis
The American Journal of Managed Care – 2026
Prevalence, Resource Utilization, and Economic Impact of Kidney Function and Proteinuria in Patients With Focal Segmental Glomerulosclerosis
The American Journal of Managed Care – 2026
Targeting Endothelin and Angiotensin Pathways for Kidney Function Preservation in Glomerular Disease
European Medical Journal – 2026
Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial
Clinical Journal of the American Society of Nephrology – 2025
Lived Experiences of Patients and Care Providers in Focal Segmental Glomerular Sclerosis and IgA Nephropathy
Glomerular Diseases – 2025
Congress materials
Results151
How Does Nephrotic-Range Proteinuria Differ From Nephrotic Syndrome in Focal Segmental Glomerulosclerosis (FSGS)?
GlomCon Hawaii – 2026
In DUPLEX, Patients With Focal Segmental Glomerulosclerosis (FSGS) Reached Low Proteinuria More Often With Sparsentan vs Irbesartan Regardless of Baseline Proteinuria
GlomCon Hawaii – 2026
The Effect of Sparsentan on Proteinuria and Urinary Inflammatory and Profibrotic Biomarkers by Baseline Proteinuria Strata in SPARTAN Study Participants With IgA Nephropathy
GlomCon Hawaii – 2026
In DUPLEX, Patients With Focal Segmental Glomerulosclerosis (FSGS) Reached Low Proteinuria More Often With Sparsentan vs Irbesartan Regardless of Baseline Proteinuria
GlomCon Hawaii – 2026
PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 Months vs >12 Months From Kidney Biopsy
GlomCon Hawaii – 2026
PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 Months vs >12 Months From Kidney Biopsy
GlomCon Hawaii – 2026
Events
Results19
Past
June 3–6, 2026 – Glasgow, Scotland
63rd European Renal Association (ERA) Congress 2026
Past
June 23, 2026 – Chicago, IL
Path 2 Progress: Chicago
Past
May 6–10, 2026 – New Orleans, LA
National Kidney Foundation (NKF) Spring Clinical Meetings 2026
Past
April 24–27, 2026 – Boston, MA
97th Pediatric Academic Societies (PAS) Meeting 2026
Past
April 25–28, 2026 – New Orleans, LA
American Nephrology Nurses Association (ANNA) National Symposium 2026
Past
April 17, 2026 – Atlanta, GA
Path 2 Progress: Atlanta
Abstracts
Results48
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Immunoglobulin A Nephropathy (IgAN)
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Patients With IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy: Preliminary Findings From the SPARTAN Trial
Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety Visual Abstract
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Immunoglobulin A Nephropathy (IgAN)
Sparsentan (SPAR) vs Irbesartan (IRB) in Patients With Focal Segmental Glomerulosclerosis (FSGS): Results From the Phase 3 DUPLEX Trial